Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DC-806 by DICE Therapeutics for Unspecified Immunological Disorders: Likelihood of Approval
DC-806 is under clinical development by DICE Therapeutics and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's DC-806?
DC-806 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's DC-806?
DC-806 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis...